China’s First Automotive-grade Solid-state LiDAR Production Line Was Launched
13.3.2021 05:30:00 EET | Business Wire | Press release
RoboSense ( https://robosense.ai/) announced the launch of China’s first automotive-grade solid-state LiDAR production line and would start mass production and delivery of the automotive-grade solid-state LiDAR RS-LiDAR-M1 for contract projects in Q2 this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210312005303/en/
(Photo: Business Wire)
At the CES2021 in January this year, RoboSense has officially unveiled the SOP version of the automotive-grade LiDAR RS-LiDAR-M1, which features a slim design, excellent performance, and reliable point cloud quality. Since July last year, the RS-LiDAR-M1 has successively received a number of orders for mass-production vehicle models around the world, among which, the first customer was an OEM from North America. In December last year, the RS-LiDAR-M1 samples were shipped to this OEM customer in batches, and became the world's first mass-production-ready automotive-grade MEMS solid-state LiDAR delivered.
Two days ago, Inceptio released the self-driving system "Xuanyuan" equipped with RoboSense solid-state LiDAR, and the two parties announced the partnership that the mass-produced L3 heavy-duty freight truck equipped with "Xuanyuan" system will be launched on the market by the end of 2021.
As a world-leading smart LiDAR supplier, RoboSense has reached in-depth cooperation with Inceptio from 2019 to provide high-performance automotive-grade MEMS solid-state LiDAR RS-LiDAR-M1 for Inceptio’s "Xuanyuan" system, the first full-stack self-developed autonomous trucking system for mass production. Inceptio develops the ULRS (ultra-long-range sensing), ARC (adaptive robust control) and FEAD (fuel-efficient autonomous driving) algorithms, and the ULRS can make the system perceive an ultra-long distance of up to 1,000 meters with a margin of error standing below 5%.
In June 2019, Inceptio has worked with Dongfeng Trucks and SINOTRUK respectively to developed L3 autonomous heavy-duty trucks. By the end of 2021, the mass-produced L3 heavy-duty trucks equipped with Inceptio’s "Xuanyuan" system with RoboSense LiDAR inside will be delivered to clients.
About RoboSense
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems incorporating LiDAR sensors, AI algorithms and IC chipsets, that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. Market-oriented, the company provides customers with various Smart LiDAR perception system solutions, including the MEMS and Mechanical types LiDAR HWs, fusion HW unit, and the AI-based fusion systems. To date, RoboSense LiDAR systems have been widely applied to the future mobility, including autonomous driving passenger cars, RoboTaxi, RoboTruck, RoboBus, automated logistics vehicles and intelligent road by domestic and international autonomous driving technology companies, OEMs, and Tier1 suppliers. https://robosense.ai/
About Inceptio
Inceptio Technology was founded in April 2018, with an aim to build a nation-wide freight network using autonomous driving trucks.
We focus on the transformation of line-haul logistics by providing a more secure, efficient, and economical Transportation-As-A-Service (Taas) to logistic customers. This is to be achieved with our automotive grade L3/L4 autonomous driving software/ hardware, developed in collaboration with major automotive manufacturers, fully integrated with mass-produced heavy-duty freight trucks. With our advanced technology and seasoned operation team, we envision to develop the most trustworthy autonomous freight service network.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210312005303/en/
Contact information
Press Contact
Cassie Gong, RoboSense PR Manager
86-15507590175
sqgong@robosense.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom